A retrospective study analyzing artificial intelligence (AI)-powered immune phenotyping to predict outcomes of immuno-oncology (IO)-based regimens in hepatocellular carcinoma
Latest Information Update: 01 Mar 2023
At a glance
- Drugs Atezolizumab (Primary) ; Bevacizumab (Primary) ; Ipilimumab (Primary) ; Nivolumab (Primary)
- Indications Liver cancer
- Focus Pharmacodynamics
Most Recent Events
- 01 Mar 2023 New trial record
- 21 Jan 2023 Results presented at the 2023 Gastrointestinal Cancers Symposium